MannKind Corp. director Steven B. Binder sold 39,051 shares of common stock on September 25, 2026, at a weighted average price of $3.29 per share. The sale was made under a Rule 10b5-1 plan established December 2, 2025; Binder directly held 713,258 shares after the transaction.
MannKind Corporation director Steven Binder filed a notice proposing to sell 39,051 common shares, with an aggregate market value of $128,477.79 and an approximate sale date of September 25, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares are listed as acquired from the issuer through performance stock units on July 15, 2026. The notice also lists three prior sales identified as 10b5-1 sales: 33,558 shares on September 10, 39,051 shares on August 7, and 52,485 shares on July 17, 2026.
MANNKIND CORP (MNKD) director Steven B. Binder reported selling 33,558 shares$3.81 per share752,309 shares
MannKind Corporation (MNKD) received a notice under Rule 144 that director Steven Binder plans to sell up to 33,558 shares of MannKind common stock through Morgan Stanley Smith Barney LLC. The shares relate to restricted stock units acquired from MannKind on July 15, 2026.
The notice also lists prior Rule 10b5-1 plan sales of MannKind common stock by Steven Binder during the preceding three months.
MannKind Corporation (MNKD) reported that on August 21, 2026 it filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the SEC. On the same date, MannKind furnished an opinion of Cooley LLP regarding the legality of the issuance and sale of the common stock described in that prospectus supplement, included as Exhibit 5.1, together with Cooley LLP’s related consent as Exhibit 23.1.
MannKind Corporation (MNKD) has filed a prospectus supplement registering for resale up to 12,853,470 shares of common stock by existing selling stockholders. This total includes 10,440,838 issued shares and 2,412,632 shares issuable upon exercise of outstanding pre-funded warrants from a July 24, 2026 private placement.
The company sold the private placement securities at $3.89 per common share and $3.88 per pre-funded warrant, with each pre-funded warrant carrying a $0.01 exercise price and no expiration until exercised, subject to a beneficial ownership limitation not to exceed 19.99%. MannKind will not receive any proceeds from the resale of these shares, though it is paying the registration and related offering expenses.
The selling stockholders may dispose of shares through various methods, including market and negotiated transactions, and may use underwriters, broker-dealers or agents. MannKind’s common stock trades on the Nasdaq Global Market under the symbol MNKD; the last reported sale price was $4.26 per share on August 20, 2026. Shares outstanding were 321,544,484 as of August 14, 2026, a baseline figure distinct from the shares registered for resale.
Rubric Capital Management LP and David Rosen reported a passive ownership position in MannKind Corporation common stock. They beneficially own 18,000,000 shares, representing 5.83% of the outstanding common stock, with shared voting and dispositive power over all reported shares and no sole power. The percentage is based on 308,950,166 shares outstanding as of April 24, 2026, as stated in MannKind’s Form 10-Q. Rubric Capital Master Fund LP has the right to receive dividends and sale proceeds from more than 5% of the common stock.
MannKind Corp director Steven B. Binder reported selling 39,051 shares of common stock on 2026-08-07 in an open-market transaction under a pre-established Rule 10b5-1 trading plan. The weighted average sale price was $4.06 per share, and Binder now directly holds 785,867 shares of MannKind common stock.
MannKind Corporation insider Steven Binder filed to sell MannKind common stock under Rule 144. The planned transaction involves up to 39,051 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing also lists recent 10b5-1 plan sales of MannKind common stock by Steven Binder, including 52,485 shares on 07/17/2026 for $212,837.17 and 16,940 shares on 05/12/2026 for $55,766.48.
MannKind Corporation reported net revenue of $109.4 million for the quarter ended June 30, 2026 and $199.5 million for the first six months of 2026, compared with $76.5 million and $154.9 million in the prior-year periods. Product sales, including Afrezza, V-Go and newly added Furoscix, totaled $127.5 million for the six months, while royalties from Tyvaso DPI contributed $65.1 million.
The company recorded a quarterly net loss of $19.0 million and a six‑month net loss of $35.7 million, versus net income of $0.7 million and $13.8 million a year earlier. Higher selling, general and administrative expense of $112.4 million, research and development of $35.2 million, amortization of acquired intangibles of $8.7 million and total interest expense of $27.3 million weighed on results. Net cash used in operating activities was $23.7 million for the six months.
As of June 30, 2026, cash, cash equivalents and restricted cash were $53.7 million, with additional short‑term investments of $58.2 million. Total liabilities were $799.5 million, including a $319.1 million term loan and liabilities related to the sale of future royalties and CVR contingent consideration, resulting in stockholders’ deficit of $67.2 million. United Therapeutics accounted for about 61% of consolidated revenues for both the three and six‑month periods. Following the 2025 scPharmaceuticals merger, the company recorded developed technology and IPR&D intangibles and goodwill, and achievement of CVR Milestone 1 in July 2026 will trigger an aggregate payout of approximately $44.8 million.